CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-18). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 527 · Search date 2026-07-18 · Methodology v0.6

NOVAROSE® rose petal extract,
does it really help with Improved skin hydration, wrinkles, and ultraviolet-related photoaging?

30-Second Summary
C
Evidence Grade C · 50 · Safety caution
Short-term skin measurements improved, but this is not evidence of actual photoaging prevention
What the
research shows
A double-blind RCT in 100 healthy adults taking 300 mg/day for 12 weeks reported improvements in hydration, transepidermal water loss, wrinkle indices, elasticity, and dermal density. Direct human evidence, however, rests essentially on this single developer-centered trial using short-term instrumental measures. It did not test ultraviolet skin damage or long-term prevention of photoaging, yielding C with 50 points.
What the
ads claim
Marketing can broaden short-term measurements into edible sunscreen, wrinkle prevention, or blocking photoaging. The trial did not compare ultraviolet exposure or photodamage incidence.
*

Useful facts when choosing a product

  • The direct RCT used 300 mg once daily for 12 weeks.
  • In Korea, products may use this individually recognized inner-beauty ingredient; the daily NOVAROSE content and recognition number should be checked.
  • Generic rose powder, rose water, and other rose-species extracts are not the same standardized product.
  • No serious adverse events occurred over 12 weeks, but long-term, pregnancy, lactation, and allergy data are limited.
Gap Measurement · Verdict 527 · C 50
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The 2026 Kim RCT assigned 100 healthy adults aged 25 to 65 years to NOVAROSE 300 mg/day or placebo for 12 weeks. Measurements of wrinkles, roughness, elasticity, dermal density, sagging, hydration, transepidermal water loss, desquamation, and brightness improved, with no serious adverse events. Four authors were affiliated with NOVAWells and three with the testing center. The paper describes the study as the first clinical evidence for this oral ingredient. Cell and animal work on Rosa gallica is mechanistic support only.

02

Why this is classified as C (50)

A positive 100-person RCT exceeds D-level evidence, but it is a developer-centered first trial of a proprietary ingredient using 12-week surrogate measurements. Hydration and wrinkles are C, while actual prevention is D, producing C with 50 points.

Counterpoint. The verdict could rise after independent replication and demonstration of clinically important, durable changes.

Rejudgment record. New verdict — A positive 100-person, 12-week trial of 300 mg/day used skin measurements, but it is the first developer-centered proprietary-ingredient study and lacks independent replication or actual photoaging-prevention outcomes

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improvement in measured skin hydration and wrinkle indicesCThe 100-person, 12-week RCT was positive, but it was the first developer-centered trial and has not been independently replicated.
Prevention of actual ultraviolet skin injury or long-term photoaging?No human trial has directly assessed actual UV-induced skin damage or long-term photoaging prevention; only instrument-measured skin parameters were reported.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Kim HN et al. 2026Randomized double-blind placebo-controlled trial12Multiple authors affiliated with NOVAWells and the testing centerWrinkles, elasticity, dermal density, hydration, transepidermal water loss, and related measuresMultiple skin measurements improved at 300 mg/day; no serious adverse events.Key
Jo S et al. 2021Preclinical cell, reconstructed-skin, and UVB mouse studyKorean research institutionsUVB wrinkles, collagen, MMP-1, and c-Raf signalingRosa gallica reduced UVB-related skin changes in mice, not human photoaging events.Mechanistic
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-18).

Kim HN, Park M, Won K, et al. Anthocyanin-Containing Rose Petal Extract for Photoaging Improvement: A 12-Week Double-Blind Placebo-Controlled Clinical Trial. J Med Food. 2026;29(4):196-204. PMID: 41788052. DOI: 10.1177/1096620X261430177.
checked
Jo S, Jung YS, Cho YR, et al. Oral Administration of Rosa gallica Prevents UVB-Induced Skin Aging through Targeting the c-Raf Signaling Axis. Antioxidants (Basel). 2021;10(11):1663. PMID: 34829534. DOI: 10.3390/antiox10111663.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none

Cite this verdict

NOVAROSE® rose petal extract x skin hydration, wrinkles, and photoaging Evidence Grade C card
[Chamgap] NOVAROSE® rose petal extract x skin hydration, wrinkles, and photoaging — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/novarose-skin-hydration-wrinkles-photoaging/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.